About Us FON Media Family Office News Luxury News FON Magazine FON Newsletters FON Videos FON Social Media Press Releases Marketplace Membership Contact Us Apply for FON+ FON+ Membership
FON News

Reporting for the family-office world.

Markets, real estate, luxury, philanthropy, aviation, technology, sports — 24 categories, written for principals and the people who advise them.

A National Intelligence Briefing With Lt. Cmdr. Steven Rogers & Engineered Tax Services Webinar

Please join the Family Office Networks Global Community for a National Intelligence Briefing webinar from Steve Rogers. Julio Gonzalez and Michael D’Onofrio will be hosting and bringing perspective from unprecedented new tax directives and real estate advantages.

Elevian: Re-Imagine Aging

Groundbreaking research by Elevian’s scientific co-founders (including three Professors from the Harvard Stem Cell Institute) demonstrated that young blood rejuvenates aged animals. They further discovered that replenishing the protein “GDF11” in aged animals can reproduce the regenerative effects of young blood – research published in Cell and Science and recognized as a top scientific breakthrough! In animal models, GDF11 has been demonstrated to treat more than a dozen age-related diseases, including heart failure, heart attacks, stroke, Type 2 diabetes, obesity, Alzheimer’s Disease, COPD/emphysema, liver failure, kidney failure and cancer Elevian has acquired exclusive worldwide patent rights to Harvard’s GDF11 technology. They are developing new medicines that target GDF11, with the potential to treat and prevent many age-related diseases at the same time. Elevian’s first application uses GDF11 to treat stroke, the #2 cause of death and #1 cause of long-term disability globally. In animal models, GDF11 promotes motor function recovery and survival after stroke. WHAT YOU WILL LEARN BY ATTENDING THE WEBINAR Aging is malleable – It is possible to accelerate, slow and even reverse biological aging. GDF11 plays an important role in aging – Preclinical results suggests that GDF11 has the potential to treat and prevent MANY age-related diseases and promote healthy aging. Elevian is an exciting investment opportunity – Including a team of leading scientists and drug development veterans, a massive market opportunity, and enormous societal benefit.

Orange Grove Bio Pre-Clinical Development Opportunity

Orange Grove Bio (“OGB”) is a preclinical drug development platform focused on driving down the cost of drug discovery and advancing therapies into clinical trials. They are partnered with leading universities to license transformational medicines. Orange Grove Bio and its university partners streamline the licensing process to speed up the development process to get drugs to market faster and to save time on-patent.
FON Weekly

Get the magazine in your inbox.

The weekly FON Weekly pulls the best of the magazine into one Wednesday-morning email. No fluff.

Protected by reCAPTCHA — the Google Privacy Policy and Terms of Service apply.